Organigram Progresses Towards 113k Kg Expected Capacity by End of 2019

Visit the OrganiGram Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.

Organigram Receives Perimeter License Amendment for Phases 4A and 4B as well as Initial 13 Cultivation Rooms in Phase 4A

Organigram meets schedule and is on track to increase target annualized production capacity to 113,000 kg¹ by the end of 2019

MONCTON, NB, April 30, 2019 /CNW/ – Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis is pleased to announce that it has received an expanded cultivation license from Health Canada in line with its previously announced Phase 4A and 4B expansion plans for its Moncton Campus.

The scope of the amendment includes approval of the following:

  • Perimeter Expansion Licensed – Representing an additional 163,000 sq ft of allocated space for 63 cultivation rooms populating the Company’s planned Phase 4A and 4B expansion, including the initial 13 cultivation rooms now approved. The approval of the perimeter for Phase 4B was received ahead of schedule, in tandem with the approval for Phase 4A.
  • 13 Incremental Cultivation Rooms – Representing 11,000 kg of immediate increased target production capacity. The remaining 18 Phase 4A cultivation rooms can now be submitted for Health Canada review.
  • Mechanical Room – Built to support all 63 cultivation rooms included in the Company’s planned Phase 4A and 4B expansion. The mechanical room houses Organigram’s state-of-the-art irrigation and water reclamation systems.
  • Additional Storage Area (Building C) and Processing Space – Built in anticipation of the Company’s future requirements for storage and processing relative to both dried cannabis and cannabis derivative products.

As a result of this approval, cannabis plants will be moved into these new rooms on a rolling basis in early May. The Company anticipates being able to harvest product from these new rooms by the end of July, based on normal cultivation timelines. Subsequent Health Canada licensing amendment submissions will follow to allow for a continuous filling of the remaining 50 Phase 4 cultivation rooms (4A (18 rooms) and 4B (32 rooms)) mirroring the successful approach utilized with the Company’s Phase 2 and 3 expansions.

We are proud to continue our legacy of delivering on our commitments. The completion of this phase of our expansion reinforces our commitment to innovation, efficiency and best-in-class operations. Being on time, this expansion reinforces our commitment to shareholders and shows our abilities with industry-leading execution.

Greg Engel, CEO, Organigram

The full Phase 4 expansion represents an aggregate of 77,000 kg of additional annual capacity and is being completed in a series of stages (4A: 26,000 kg; 4B:27,000 kg; and 4C: 24,000 kg) which, once fully licensed and operational, is expected to bring the Company’s annualized target production to approximately 113,000 kg by the end of calendar 2019.

A Phase 5 refurbishment is also underway for an edibles and derivative facility and additional in-house extraction capacity.

“Our stalwart commitment to our customers is reflected in our ongoing investment in exceptional processes and delivering exceptional products,” says Engel.

¹The forward-looking estimates of additional production capacity are based on a number of material factors and assumptions. Please see the Company’s most recent MD&A available on SEDAR at www.sedar.com and the disclaimer at the end of this release.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Organigram is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

Original press release

For fact-based information on Organigram, view the company’s sponsored Investor Dashboard.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter